Maxim Group Initiates Coverage on BioPharmX Corp(NYSEMKT:BPMX). The shares have been rated Buy. The rating by Maxim Group was issued on Apr 14, 2016.
BioPharmX Corp (BPMX) remained unchanged at the close of Monday session. Even as the volume increased to 1,98,858 ,the shares failed to make any impression and ended at 0 points or 0.00% at $0.85. The trading session commenced at $0.876 and the stock hit a high of $0.92 and touched $0.83 at the lower end. Considering that the stock pared all of the losses, it can be said as a positive sign. The share price has a 52-week high of $4.5 and the 52-week low is $0.83. The company has a market cap of $18 M and has approximately 2,10,89,101 outstanding shares.
BioPharmX Corp(BPMX) last announced its earnings results on Dec 14, 2015 for Fiscal Year 2015 and Q3.Company reported revenue of $20.00K. Analysts had an estimated revenue of $20.00K. Earnings per share were $-0.18. Analysts had estimated an EPS of $-0.19.
Several Insider Transactions has been reported to the SEC. On Jan 15, 2016, Stephen Morlock (director) purchased 12,000 shares at $1.52 per share price.
BioPharmX Corporation is a specialty pharmaceutical company focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter or OTC products that address markets in women’s health and dermatology. The Company’s portfolio of product candidates includes two clinical stage product candidates: BPX01 a topical antibiotic for the treatment of acne and BPX03 a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition or FBC and cyclic mastalgia. The Company’s commercial product VI2OLET iodine is an OTC dietary supplement molecular iodine tablet that promotes breast health and is for the alleviation of benign breast pain associated with fibrocystic breast condition or FBC. The Company has one wholly owned subsidiary BioPharmX Inc.